Amarin Corp Plcuk (AMRN) Share-based Compensation (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Share-based Compensation of $2.1 million for Q2 2026, down 65.23% year-over-year from $6.0 million in Q2 2025, and down 9.91% quarter-over-quarter from $2.3 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Share-based Compensation (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Share-based Compensation for 17 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation fell 65.23% year-over-year to $2.1 million; the TTM figure through Jun 2026 stood at $8.0 million (down 56.67% YoY), while the FY2025 annual figure was $13.9 million, down 21.28% from the prior year.
- Share-based Compensation fell to $2.1 million in Q2 2026 per AMRN's latest filing, from $2.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.6 million in Q2 2022 and bottomed at $1.6 million in Q4 2025.
- Historically, Share-based Compensation has averaged $4.4 million across 5 years, with a median of $4.5 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 248.77% — and 2023, when it tumbled 78.78%.
- Amarin Corp Plc\Uk's Share-based Compensation stood at $6.6 million in 2022, then dropped by 19.83% to $5.3 million in 2023, then slumped by 35.82% to $3.4 million in 2024, then tumbled by 52.53% to $1.6 million in 2025, then surged by 30.03% to $2.1 million in 2026.
- Business Quant data shows AMRN's Share-based Compensation at $2.1 million in Q2 2026, $2.3 million in Q1 2026, and $1.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.75 Bn | 633.00 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 469.96 Bn | 463.39 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 376.93 Bn | 369.79 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.25 Bn | 295.56 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.53 Bn | 252.63 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.22 Bn | 222.23 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 182.19 Bn | 179.01 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.27 Bn | 102.10 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.87 Bn | 5.56 Bn | 14.99 Mn | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Mar 31, 2024 | 5.22 Mn |